Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

Analysts have suggested that approval for AAD could swell sales of Rexulti by $500 million to $1 billion, a big step up for a drug which currently makes around $1.4 billion in annual sales.

got a pharmaceutical option last year when the FDA approved the antipsychotic drug Rexulti (Brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s disease.

Lundbeck and Otsuka’s Rexulti took fifth ... All together, the 10 biggest spenders laid out $248 million on TV drug ad spending in March—leveling out to a happy medium between January ...

The US Food and Drug Administration (FDA ... In 2023, Otsuka Pharmaceuticals’ Rexulti (brexpiprazole) became the first FDA-approved treatment for agitation associated with Alzheimer's in ...

Industry veteran Charmaine Lykins to helm Transneural as it transforms the treatment of neuropsychiatric disorders ISSAQUAH, WASHINGTON / ACCESS Newswire / April 22, 2025 / CaaMTech, Inc. has spun out ...